Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy.

Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy.
复制标题

DOI:
10.1377/hlthaff.2020.02054
复制
发表时间:
2021-01
期刊:
Health affairs (Project Hope)
影响因子:
--
通讯作者:
Walensky RP
Walensky RP
中科院分区:
其他
文献类型:
--
作者:
Paltiel AD;Schwartz JL;Zheng A;Walensky RP

文献摘要

参考文献

被引文献

相似文献

全球开发 COVID-19 疫苗的努力可能很快就会生产出一种或多种授权疫苗。我们研究了疫苗功效的不同定义和阈值,加上不同水平的实施有效性和背景流行病严重程度,如何转化为包括累积感染、住院和死亡在内的结果。通过对高危人群的疫苗接种进行数学模拟,我们发现与实施相关的因素比临床试验中确定的疫苗功效对疫苗接种计划的成功贡献更大。如果生产或部署延迟、疫苗犹豫不决或流行病更加严重,疫苗的益处将大幅下降。我们的研究结果强调,卫生官员需要迅速采取行动,扩大生产和分配基础设施的规模,以提高公众对 COVID-19 疫苗的广泛信心,并鼓励继续遵守其他缓解策略,即使在疫苗问世之后也是如此。
The global effort to develop a COVID-19 vaccine is likely to soon produce one or more authorized vaccines. We examine how different definitions and thresholds of vaccine efficacy, coupled with different levels of implementation effectiveness and background epidemic severity, translate into outcomes including cumulative infections, hospitalizations, and deaths. Using a mathematical simulation of vaccination in an at-risk population, we find that factors related to implementation will contribute more to the success of vaccination programs than the efficacy of a vaccine as determined in clinical trials. The benefits of a vaccine will decline substantially in the event of manufacturing or deployment delays, vaccine hesitancy, or greater epidemic severity. Our findings highlight the need for health officials to move swiftly to scale up production and distribution infrastructure, to promote widespread public confidence in COVID-19 vaccines, and to encourage continued adherence to other mitigation strategies, even after a vaccine becomes available.
DOI: 10.1001/jamanetworkopen.2020.21892
发表时间: 2020-09-01
期刊: JAMA network open
影响因子: 13.8
作者:
Muñoz-Price LS;Nattinger AB;Rivera F;Hanson R;Gmehlin CG;Perez A;Singh S;Buchan BW;Ledeboer NA;Pezzin LE
通讯作者: Pezzin LE
DOI: 10.1016/s0140-6736(20)32009-2
发表时间: 2020-10-24
期刊: Lancet (London, England)
影响因子: --
作者:
Anand S;Montez-Rath M;Han J;Bozeman J;Kerschmann R;Beyer P;Parsonnet J;Chertow GM
通讯作者: Chertow GM
在未来5年中,免疫生活史,疫苗接种和SARS-COV-2的动态。
DOI: 10.1126/science.abd7343
发表时间: 2020-11-13
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Saad-Roy CM;Wagner CE;Baker RE;Morris SE;Farrar J;Graham AL;Levin SA;Mina MJ;Metcalf CJE;Grenfell BT
通讯作者: Grenfell BT
DOI: 10.1001/jama.2020.6130
发表时间: 2020-05-19
影响因子: 120.7
作者:
Pan, An;Liu, Li;Wu, Tangchun
通讯作者: Wu, Tangchun
DOI: 10.1038/s41586-020-2607-z
发表时间: 2020-10
期刊: Nature
影响因子: 64.8
作者:
Mercado NB;Zahn R;Wegmann F;Loos C;Chandrashekar A;Yu J;Liu J;Peter L;McMahan K;Tostanoski LH;He X;Martinez DR;Rutten L;Bos R;van Manen D;Vellinga J;Custers J;Langedijk JP;Kwaks T;Bakkers MJG;Zuijdgeest D;Rosendahl Huber SK;Atyeo C;Fischinger S;Burke JS;Feldman J;Hauser BM;Caradonna TM;Bondzie EA;Dagotto G;Gebre MS;Hoffman E;Jacob-Dolan C;Kirilova M;Li Z;Lin Z;Mahrokhian SH;Maxfield LF;Nampanya F;Nityanandam R;Nkolola JP;Patel S;Ventura JD;Verrington K;Wan H;Pessaint L;Van Ry A;Blade K;Strasbaugh A;Cabus M;Brown R;Cook A;Zouantchangadou S;Teow E;Andersen H;Lewis MG;Cai Y;Chen B;Schmidt AG;Reeves RK;Baric RS;Lauffenburger DA;Alter G;Stoffels P;Mammen M;Van Hoof J;Schuitemaker H;Barouch DH
通讯作者: Barouch DH